Atossa Genetics Stock Analysis
| ATOS Stock | USD 4.05 0.77 15.98% |
Atossa Genetics' financial leverage is the degree to which the firm utilizes its fixed-income securities and uses equity to finance projects. Companies with high leverage are usually considered to be at financial risk. Atossa Genetics' financial risk is the risk to Atossa Genetics stockholders that is caused by an increase in debt. In other words, with a high degree of financial leverage come high-interest payments, which usually reduce Earnings Per Share (EPS).
Given that Atossa Genetics' debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which Atossa Genetics is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of Atossa Genetics to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, Atossa Genetics is said to be less leveraged. If creditors hold a majority of Atossa Genetics' assets, the Company is said to be highly leveraged.
Atossa Genetics is fairly valued with Real Value of 4.01 and Hype Value of 4.05. The main objective of Atossa Genetics stock analysis is to determine its intrinsic value, which is an estimate of what Atossa Genetics is worth, separate from its market price. There are two main types of Atossa Genetics' stock analysis: fundamental analysis and technical analysis.
The Atossa Genetics stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. Atossa Genetics is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day ( substitute day ), Independence Day. Atossa Stock trading window is adjusted to America/New York timezone.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atossa Genetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. Atossa Stock Analysis Notes
About 19.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.86. Some equities with similar Price to Book (P/B) outperform the market in the long run. Atossa Genetics recorded a loss per share of 3.33. The entity last dividend was issued on the 20th of April 2018. The firm had 1:15 split on the 2nd of February 2026. Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington. Atossa Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 6 people. For more info on Atossa Genetics please contact FCAP MD at 206 588 0256 or go to https://www.atossatherapeutics.com.Atossa Genetics Investment Alerts
| Atossa Genetics generated a negative expected return over the last 90 days | |
| Atossa Genetics has high historical volatility and very poor performance | |
| Net Loss for the year was (25.5 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Atossa Genetics currently holds about 125.54 M in cash with (21.03 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.99. |
Atossa Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 41.51 M.Technical Drivers
As of the 11th of February 2026, Atossa Genetics shows the Risk Adjusted Performance of (0.18), standard deviation of 6.38, and Mean Deviation of 4.06. Atossa Genetics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Atossa Genetics variance and potential upside to decide if Atossa Genetics is priced correctly, providing market reflects its regular price of 4.05 per share. Given that Atossa Genetics has information ratio of (0.26), we suggest you to validate Atossa Genetics's prevailing market performance to make sure the company can sustain itself at a future point.Atossa Genetics Price Movement Analysis
Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Weighted Moving Average calculates a weight for each value in Atossa Genetics price series with the more recent values given greater weights.
Atossa Genetics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Atossa Genetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Atossa Genetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Atossa Genetics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Atossa Genetics Outstanding Bonds
Atossa Genetics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Atossa Genetics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Atossa bonds can be classified according to their maturity, which is the date when Atossa Genetics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
Atossa Genetics Predictive Daily Indicators
Atossa Genetics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Atossa Genetics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 54008.99 | |||
| Daily Balance Of Power | (1.04) | |||
| Rate Of Daily Change | 0.84 | |||
| Day Median Price | 4.4 | |||
| Day Typical Price | 4.28 | |||
| Price Action Indicator | (0.74) | |||
| Period Momentum Indicator | (0.77) |
Atossa Genetics Forecast Models
Atossa Genetics' time-series forecasting models are one of many Atossa Genetics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Atossa Genetics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.Atossa Genetics Debt to Cash Allocation
Many companies such as Atossa Genetics, eventually find out that there is only so much market out there to be conquered, and adding the next product or service is only half as profitable per unit as their current endeavors. Eventually, the company will reach a point where cash flows are strong, and extra cash is available but not fully utilized. In this case, the company may start buying back its stock from the public or issue more dividends.
Atossa Genetics currently holds 4.97 M in liabilities. Atossa Genetics has a current ratio of 34.49, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Atossa Genetics' use of debt, we should always consider it together with its cash and equity.Atossa Genetics Assets Financed by Debt
Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Atossa Genetics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Atossa Genetics, which in turn will lower the firm's financial flexibility.Atossa Genetics Corporate Bonds Issued
About Atossa Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how Atossa Genetics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Atossa shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Atossa Genetics. By using and applying Atossa Stock analysis, traders can create a robust methodology for identifying Atossa entry and exit points for their positions.
Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines in the areas of oncology and infectious diseases. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington. Atossa Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 6 people.
Be your own money manager
As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Atossa Genetics to your portfolios without increasing risk or reducing expected return.Did you try this?
Run Technical Analysis Now
Technical AnalysisCheck basic technical indicators and analysis based on most latest market data |
| All Next | Launch Module |
Additional Tools for Atossa Stock Analysis
When running Atossa Genetics' price analysis, check to measure Atossa Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atossa Genetics is operating at the current time. Most of Atossa Genetics' value examination focuses on studying past and present price action to predict the probability of Atossa Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atossa Genetics' price. Additionally, you may evaluate how the addition of Atossa Genetics to your portfolios can decrease your overall portfolio volatility.